Tradestie Institutional Equity Comparison Engine
STLN vs SABS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SABS Overall Edge
SABS Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to SAB Biotherapeutics, Inc. Common Stock (SABS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, STLN trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus SABS at N/M Forward P/E and 0.0% operating margin (-62.4% YoY). In options structure, STLN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SABS sits in CONSOLIDATION (21st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
STLN N/M vs SABS N/M Fwd P/E
Growth & Margin Winner
SABS
Op Margin N/A vs 0.0% ยท YoY N/A vs -62.4%
Momentum & Technical Winner
SABS
1Y -42.0% vs -26.6% ยท 52W Pos 1% vs 14%
Options & Structure Winner
SABS
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (21st %ile IV)
STLN
US Equity
STLN
Institutional Equity
$3.00
-5.66% 1D
Market Cap
N/A
1M Return
-56.58%
1Y Return
-41.97%
Forward P/E
N/M
Unified AI Score
46.6 / 100
HOLD
Tech 45.0
Fund 46.0
Flow 50.0
Mom 55.0
SABS
NASDAQ
SAB Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$2.81
-3.44% 1D
Market Cap
$262.2M
1M Return
-7.57%
1Y Return
-26.63%
Forward P/E
N/M
Unified AI Score
37.4 / 100
SELL
Tech 20.0
Fund 52.0
Flow 67.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
STLN -41.97%
SABS -26.63%
Spread: +14.96 pp (SABS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
STLN TTM Op. Margin: N/A
SABS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on STLN vs SABS. Trailing 12-month operating profitability (STLN N/A vs SABS 0.0%) and valuation multiples (STLN N/M vs SABS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | STLN | SABS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $262.2M | Larger Scale | SABS |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | N/A | -62.4% | Higher Growth | SABS |
| Operating Margin (TTM) Profitability | N/A | 0.0% | Higher Margin | SABS |
| Net Profit Margin Profitability | N/A | 0.0% | Higher Margin | SABS |
| Return on Equity (ROE) Capital Efficiency | N/A | -42.8% | Higher ROE | SABS |
| 52-Week Range Position Momentum | 1% ($3โ$7) | 14% ($2โ$5) | Stronger Trend | SABS |
| Beta / 30D Volatility Risk Regime | 1.42ฮฒ ยท 175% Vol | 1.38ฮฒ ยท 76% Vol | Lower Realized Risk | SABS |
| Unified Institutional Score Composite Signal | 46.6 / 100 (HOLD) | 37.4 / 100 (SELL) | Higher Composite | STLN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full STLN vs SABS Buy Guide
STLN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SABS
CONSOLIDATION
15d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
21st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither STLN nor SABS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.